← Eichor
Condition: Fibrosarcoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Fibrosarcoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Tango Therapeutics, Inc. · NCT05732831Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
Phase N/A · 13 location(s) · Washington University School of Medicine · NCT03141021Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma
Phase 2 · 1 location(s) · Eva Marie Erfurth, MD, PhD · NCT05525273IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
Phase 2 · 1 location(s) · Fudan University · NCT06849986DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Asses
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT07298083Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the
NA · 20 location(s) · Institut Claudius Regaud · NCT03967834Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Phase 1 · 2 location(s) · National Cancer Institute (NCI) · NCT04222413A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning
NA · 3 location(s) · Ricoh USA, Inc. · NCT06387485Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Adv
Phase 1 · 16 location(s) · National Cancer Institute (NCI) · NCT05711615Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.
Phase 2 · 2 location(s) · Oslo University Hospital · NCT07173972Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Phase 1 · 25 location(s) · Bristol-Myers Squibb · NCT05245500NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and S
Phase 1/Phase 2 · 7 location(s) · St. Jude Children's Research Hospital · NCT06239272A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT04872543SPEARHEAD-3 Pediatric Study
Phase 1/Phase 2 · 10 location(s) · USWM CT, LLC · NCT05642455Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
Phase 1/Phase 2 · 2 location(s) · AeRang Kim · NCT06735820Agnostic Therapy in Rare Solid Tumors
Phase 2 · 8 location(s) · Instituto do Cancer do Estado de São Paulo · NCT06638931A Study of DEG6498 in Participants With Solid Tumors
Phase 1 · 3 location(s) · Degron Therapeutics Co. · NCT07244835A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Phase 1 · 10 location(s) · Epkin · NCT06789172Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT06222203A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Phase 2 · 16 location(s) · Memorial Sloan Kettering Cancer Center · NCT05985161A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
Phase 3 · 13 location(s) · Rezolute · NCT06881992A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Phase 1/Phase 2 · 68 location(s) · Turning Point Therapeutics, Inc. · NCT04094610B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Phase 1 · 1 location(s) · St. Jude Children's Research Hospital · NCT04897321A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07089992A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT04332874Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma
Phase 2 · 4 location(s) · Oslo University Hospital · NCT07169344MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
Phase 2 · 1 location(s) · HRYZ Biotech Co. · NCT06277154Neurofibromatosis Type 1 Tumor Early Detection Study
Phase N/A · 1 location(s) · David Miller · NCT06515860
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.